Ikena Oncology, Inc. has announced that Institutional Shareholder Services Inc. and Glass, Lewis & Co. recommend stockholders vote in favor of the proposed merger with Inmagene Biopharmaceuticals. This merger involves the issuance of shares as outlined in the company's proxy vote proposal. Inmagene, a privately held biopharmaceutical company, is developing IMG-007, an anti-OX40 monoclonal antibody with potential applications in the I&I space. Ikena's CEO, Mark Manfredi, expressed optimism about the merger, citing recent progress in treating patients in a Phase 2B study for atopic dermatitis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.